Primary care professionals (HCPs) are key to the early identification of Alzheimer’s disease (AD) and other cognitive impairments (CIs). Brain health discussions and cognitive screening are critical, as recent American Heart Association (AHA)/American Stroke Association (ASA) statements/guidelines have reaffirmed that U.S. dementia cases are estimated to triple by 2050. However, there is currently a lack of standard practice protocols for how HCPs should engage patients and families in brain health discussions and conduct cognitive assessments in primary care settings. Consequently, CI often goes unrecognized more than 50% of the time in patients age > 70, with a delay of 3 years from start of symptoms to diagnosis of AD. Clinicians should optimize discussions on brain health early and routinely and screen for CI as part of annual wellness exams to detect CI onset while mild.
Please join expert faculty for this CMEO video webcast on best practices for diagnosing CIs. The activity will include strategies for engaging patients in discussions on brain health, integrating cognitive screenings into wellness visits, employing appropriate follow-up and referral, and implementing a coordinated care approach.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Genentech, a member of the Roche Group.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and psychologists specializing in primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Tangalos reports the following financial relationships: Research Support: National Institutes of Health (NIH); Consultant: Acadia Pharmaceuticals Inc.; Biogen; Eisai Inc.; and Genentech, Inc.; Stock Shareholder (direct purchase): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc. Other Financial or Material Support: Alzheimer’s Association (Project ECHO course director); Cyclo Therapeutics, Inc. Data and Safety Monitoring Board (DSMB); and Prothena DSMB
Dr. Cohen reports no financial relationships to disclose.
Dr. Sadak reports the following financial relationships: Advisory Board: Board of Directors, National Hartford Center of Gerontological Nursing Excellence; Board of Directors, DeTornyay Center for Healthy Aging; WA State Nursing Care Quality Assurance Commission, Critical Gaps in LTC; and WA Dementia Action Collaborative. Grants and Research Support: National Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Washington Department of Social & Health Services/Health Care Authority (WA DSHS/HCA).
Dr. Hempstead (content reviewer) reports the following financial relationships: Financial and Material Support: Alzheimer’s Association ISTAART Nonpharmacologic Intervention (Professional Interest Area Chair International); Neuropsychological Society (Chair of Continuing Education Committee); Oxford University Press (book royalties); and Soterix Medical Inc. (Licensed neuromodulation headgear device)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.